The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 2	2024-02-12		NCT06254690

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Affiliated Hospital of Jiangnan University	18
Affiliated Hospital of Jiangsu University	7
Affiliated Hospital of Nantong University	71
Anhui Provincial Cancer Hospital	32
Huai'an First People's Hospital	20
Jingjiang People's Hospital	2
Suzhou Municipal Hospital	28
The Affiliated Hospital of Xuzhou Medical University	68
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	164
The First Affiliated Hospital with Nanjing Medical University	319
Yancheng First People's Hospital	11
Zhongda Hospital	46

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Jiangsu Provincial People's Hospital	Nanjing	China	21